HDAC9 and acute myeloid leukemia: In our study, the traditional cytotoxic drugs were more sensitive in the low-risk group and included histone deacetylase (HDAC) inhibitors, such as vorinostat and parthenolide (Figure 9A,B), the BCL-2 inhibitor navitoclax (Figure 9C), and midostaurin (Figure 9D), which were demonstrated to consolidate chemotherapy and encourage efficacy in AML patients with a FLT3 mutation [20].